The notion that ER+ cancer is of a different nature in BRCA2 mutation carriers than in sporadic cases is further supported by findings of higher Oncotype DX Breast Recurrence Scores for BRCA-associated versus sporadic ER+ cancer19–21 and by the observation that mortality among ER+ BRCA2 carriers is higher than expected by the PREDICT model22. Here, BRCA2 is linked to cancer.